CCR1 and candidiasis: A follow-up study of a pharmacological blockade of CCR1 with BL5923 in immunocompetent mice infected with systemic candidiasis in vivo resulted in significant improved survival rates 2-weeks post-infection (50%), longer median survival time (10 days vs 3 days), decreased tissue fungal burden in the kidney (p = 0.0185), and less extensive renal tissue invasion when compared to the control mice (90).